GSK (GSK) Projected to Announce Earnings on Wednesday

GSK (NYSE:GSK) is expected to announce its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect GSK to post earnings of $1.33 per share and revenue of $11.78 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

GSK (NYSE:GSK) last released its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter in the prior year, the firm posted $0.47 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. On average, analysts expect GSK to post $4.78 EPS for the current fiscal year and $5.00 EPS for the next fiscal year.

GSK Stock Performance

NYSE GSK opened at $51.10 on Tuesday. The business has a 50 day moving average price of $49.58 and a 200 day moving average price of $52.36. The company has a market capitalization of $103.37 billion, a P/E ratio of 15.98, a PEG ratio of 2.28 and a beta of 0.33. GSK has a 1-year low of $42.88 and a 1-year high of $61.69. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

Analysts Set New Price Targets

GSK has been the topic of several research reports. Royal Bank Of Canada started coverage on GSK in a report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. JPMorgan Chase & Co. restated a “sell” rating on shares of GSK in a research report on Thursday, October 1st. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a research report on Monday, September 28th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. Four analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, GSK presently has a consensus rating of “Hold” and a consensus price target of $55.33.

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.